Publication: Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients.
No Thumbnail Available
Identifiers
Date
2020-11-05
Authors
Martín-Aguilar, Lorena
Camps-Renom, Pol
Lleixà, Cinta
Pascual-Goñi, Elba
Díaz-Manera, Jordi
Rojas-García, Ricardo
De Luna, Noemi
Gallardo, Eduard
Cortés-Vicente, Elena
Muñoz, Laia
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
To study baseline serum neurofilament light chain (sNfL) levels as a prognostic biomarker in Guillain-Barré syndrome (GBS). We measured NfL in serum (98 samples) and cerebrospinal fluid (CSF) (24 samples) of patients with GBS prospectively included in the International GBS Outcome Study (IGOS) in Spain using single-molecule array (SiMoA) and compared them with 53 healthy controls (HCs). We performed multivariable regression to analyse the association between sNfL levels and functional outcome at 1 year. Patients with GBS had higher NfL levels than HC in serum (55.49 pg/mL vs 9.83 pg/mL, p319 pg/mL), inability to run (>248 pg/mL) and ability to run (248 pg/mL) and ability to run ( Baseline sNfL levels are increased in patients with GBS, are associated with disease severity and axonal variants and have an independent prognostic value in patients with GBS.